Analyzing UnitedHealth (UNH) Through an Investor's Lens

By Emilio Sanchez • Wednesday, August 27 10:04 • Permanent Link

Large-cap Health Care company UnitedHealth has moved 0.9% so far today on a volume of 2,704,714, compared to its average of 16,408,900. In contrast, the S&P 500 index moved 0.0%.

UnitedHealth trades -7.55% away from its average analyst target price of $328.04 per share. The 24 analysts following the stock have set target prices ranging from $198.0 to $626.0, and on average have given UnitedHealth a rating of buy.

If you are considering an investment in UNH, you'll want to know the following:

UnitedHealth's current price is 57.8% above its Graham number of $192.13, which implies that at its current valuation it does not offer a margin of safety
UnitedHealth has moved -49.0% over the last year, and the S&P 500 logged a change of 15.6%
Based on its trailing earnings per share of 23.1, UnitedHealth has a trailing 12 month Price to Earnings (P/E) ratio of 13.1 while the S&P 500 average is 29.3
UNH has a forward P/E ratio of 10.1 based on its forward 12 month price to earnings (EPS) of $29.9 per share
Its Price to Book (P/B) ratio is 2.9 compared to its sector average of 3.19
UnitedHealth Group Incorporated operates as a health care company in the United States and internationally.
Based in Eden Prairie, the company has 400,000 full time employees and a market cap of $274.66 Billion. UnitedHealth currently returns an annual dividend yield of 2.8%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.